Be first to read the latest tech news, Industry Leader's Insights, and CIO interviews of medium and large enterprises exclusively from Healthcare Tech Outlook
THANK YOU FOR SUBSCRIBING
Transmural Biotech : Spearheading Innovation in Biotechnology
Follow Transmural Biotech on :
Irene Rodríguez Ausucua, Head of External Relations, Transmural Biotech
The rapid pace of technological, medical and scientific innovation is transforming the narrative in the biopharma industry. With the increasing need for better patient engagement and experience, the industry is testing the Artificial Intelligence (AI) waters in areas such as diagnostics. In addition, the aftermath of the COVID-19 pandemic has ushered in a plethora of opportunities for sectors such as biotechnology, which has emerged as one of the most attractive sectors for investors.
The industry has consolidated its position, as has happened in a sector as countercyclical as healthcare. However, Covid-19 has put an end to the certainties that biotechnology had controlled on the horizon of pandemics. On the other hand, some sectors have seen their position strengthened, such as cancer prevention through the treatment of medical images by AI. AI holds immense potential and capability to enable a digitally transformed biopharma company. When it comes to contemporary medicine, AI has been instrumental in the digitalisation of the industry, significantly influencing the detection capacity or dynamisation of processes.
Set against this rapidly transforming backdrop, if there is one company that can be credited for the advancement of AI in the biotechnology space, it’s Transmural Biotech. A spin-off of the Hospital Clinic of Barcelona and the University of Barcelona, Transmural Biotech was born to improve healthcare worldwide and positively impact the health of more people each day. At the core, Transmural Biotech specialises in innovative medical technologies based on image analysis and processing to provide health professionals with additional information that current technologies cannot offer and substantially improve the quality of service they can offer the patient. Established in 2009 by expert medical and engineering professionals, Transmural Biotech contributes to the biotechnology space’s transformation by developing medical technologies based on image diagnosis through AI.
Transmural Biotech currently offers two primary platforms for image-based AI and algorithms as a predictive basis for medical diagnosis. “In collaboration with the medical institutions that provide us with images, we have created algorithms for a very wide range of diseases in all types of ages. We are building AI algorithms capable of diagnosing—through images —a wide range of very dangerous diseases. Through these images, embracing the notion of non-invasive tests, Transmural Biotech builds algorithms with excellent predictive capacity that are capable of advancing diagnosis with an immediate response,” says Irene Rodríguez Ausucua, Head of External Relations, Transmural Biotech.
At the centre of these efforts is Transmural Biotech’s new product, quantusSKIN—a non-invasive, fast and easy-to-use test for detecting malignant dermatological lesions from dermoscopic images. quantusSKIN is powered by technology based on quantitative analysis of dermoscopic image texture.
Transmural Biotech builds algorithms with excellent predictive capacity that are capable of advancing diagnosis with an immediate response
By simply analysing and classifying images, quantusSKIN determines the risk of skin lesion malignancy within minutes. quantusSKIN determines the risk of skin lesion malignancy within minutes and returns a percentage that the nevus included in the image is malignant (melanoma, basal cell carcinoma or squamous cell carcinoma). quantusSKIN has been designed with a clear focus on the general population and aims to be of great help in screening patients with risk factors and prioritising waiting lists. The product’s possibilities will be diverse, ranging from a medical office in primary care to the dermatology units, and dermatological and aesthetic clinics. The non-invasive procedure, reliability and quick turnaround time are the winning differentiators of the quantusSKIN test. Demonstrating excellent sensitivity and specificity values, the test is performed with a simple dermatoscopic image obtained with a smartphone or reflex camera, which produces reports in the same office in a matter of minutes.
Touching upon the value Transmural Biotech brings to the table with AI, Irene emphasises the role of AI in anticipatory capacity in detection and diagnostic assistance. She adds that the technology is opening up new avenues for the capacity for detection, advanced triage and anticipation in the use of treatments. “The raw material of AI is the images, not the machines; the algorithms for early diagnosis are derived from the analysis of these images. In other words, there is no artificial basis that can replace the intelligent analysis of millions of correctly classified images,” informs Irene.
Carving a Niche in Biotechnology When asked about what steers Transmural Biotech ahead of the competition, Irene’s response is as instant as it can get. “Our distinctiveness lies in the transversal and vanguard features of our solutions, coupled with our commitment to excellence in research and development and the belief to an ethical commercialisation of medical technologies that allow us to substantially improve the care that patients receive,” she remarks. Besides, given that the utilisation of AI in the industry is still in its infancy, Transmural Biotech has evolved one of the earliest companies making predictive algorithms based on the application of AI to medical images. While there is an increasing proliferation of AI to study health data, pathogens’ genetic material, and personalise medical treatments, the images frontier has not been tapped much by the technology. This is where Transmural Biotech is moving the needle.
With global distribution in countries across Latin America, North America, Europe and Asia, Transmural Biotech is now focused on identifying and developing new technologies such as the Internet to maximise the use, accessibility and competitiveness of its products and personalised products clinical service. For the future, Transmural Biotech is working to find medically well-informed alliances that provide quality images, along with forging marketing agreements in geographic areas and collaboration with medical imaging equipment manufacturers. “We are looking forward to finding medical institutions that provide us with images, to create algorithms for a very wide range of diseases in all types of ages; if we get enough informed medical images, in less than six months, we will be able to find algorithms capable of predicting them in advance,” concludes Irene.
Management Irene Rodríguez Ausucua, Head of External Relations , Transmural Biotech
Description Transmural Biotech specialises in innovative medical technologies based on image analysis and processing to provide health professionals with additional information that current technologies cannot provide and substantially improve the quality of service they can offer the patient
This content is copyright protected
However, if you would like to share the information in this article, you may use the link below: